WO2008038160A3 - Substance à effet sédatif - Google Patents
Substance à effet sédatif Download PDFInfo
- Publication number
- WO2008038160A3 WO2008038160A3 PCT/IB2007/004218 IB2007004218W WO2008038160A3 WO 2008038160 A3 WO2008038160 A3 WO 2008038160A3 IB 2007004218 W IB2007004218 W IB 2007004218W WO 2008038160 A3 WO2008038160 A3 WO 2008038160A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substance
- patients
- pyrone
- gamma
- days
- Prior art date
Links
- 239000000126 substance Substances 0.000 title abstract 4
- 206010029333 Neurosis Diseases 0.000 title abstract 2
- 208000015238 neurotic disease Diseases 0.000 title abstract 2
- 230000001624 sedative effect Effects 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- UUUICOMMFFTCHS-UHFFFAOYSA-N 5-hydroxy-4-oxopyran-2-carboxylic acid Chemical compound OC(=O)C1=CC(=O)C(O)=CO1 UUUICOMMFFTCHS-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- ZEGRKMXCOCRTCS-UHFFFAOYSA-N Poppy acid Chemical compound OC(=O)C1=CC(=O)C(O)=C(C(O)=O)O1 ZEGRKMXCOCRTCS-UHFFFAOYSA-N 0.000 abstract 1
- CVQUWLDCFXOXEN-UHFFFAOYSA-N Pyran-4-one Chemical compound O=C1C=COC=C1 CVQUWLDCFXOXEN-UHFFFAOYSA-N 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- LIVNCPMCQTZXRZ-UHFFFAOYSA-N meconic acid Natural products CC(=O)C1=CC(=O)C(O)=C(C(C)=O)O1 LIVNCPMCQTZXRZ-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 238000007910 systemic administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une substance à effet sédatif, qui comprend une dose thérapeutiquement efficace d'un gamma-pyrone, tel que l'acide coménique, l'acide méconique, l'acide 5-méthoxy-gamma-pyrone-2-carboxylique et analogues, dans un support pharmaceutiquement acceptable. Administrée selon une posologie quotidienne de 0,05 mg à environ 10 000 mg du principe actif par dose unitaire d'un patient, la substance de l'invention peut servir à traiter divers troubles du système nerveux, par exemple la douleur, l'insomnie, l'anxiété, la névrose, la dépression, ainsi que des symptômes de sevrage chez des patients toxicomanes, en particulier des patients dépendants des opiacés. La substance de l'invention peut être administrée selon plusieurs voies d'administration systémique d'un agent pharmaceutique, notamment l'administration par voie orale, parentérale, transdermique ou transmuqueuse. Pour les patients toxicomanes, le procédé d'administration préféré implique un implant sous-cutané assurant une libération continue d'un principe actif, selon une dose quotidienne efficace, pendant toute la durée du traitement s'étalant entre 5 et 30 jours, de préférence, entre 13 et 20 jours.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/459,659 | 2006-07-25 | ||
| US11/459,659 US20060252824A1 (en) | 2002-03-19 | 2006-07-25 | Substance with sedative effect |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2008038160A2 WO2008038160A2 (fr) | 2008-04-03 |
| WO2008038160A3 true WO2008038160A3 (fr) | 2008-07-24 |
Family
ID=39230613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2007/004218 WO2008038160A2 (fr) | 2006-07-25 | 2007-06-21 | Substance à effet sédatif |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008038160A2 (fr) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003079976A2 (fr) * | 2002-03-19 | 2003-10-02 | Technology Commercialization Corp. | Substance ayant une action sedative |
-
2007
- 2007-06-21 WO PCT/IB2007/004218 patent/WO2008038160A2/fr active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003079976A2 (fr) * | 2002-03-19 | 2003-10-02 | Technology Commercialization Corp. | Substance ayant une action sedative |
| US20060252824A1 (en) * | 2002-03-19 | 2006-11-09 | Krylov Boris V | Substance with sedative effect |
Non-Patent Citations (3)
| Title |
|---|
| DERBENEV A V ET AL: "Effects of meconic and comenic acids on slow sodium channels of secondary neurons.", MEMBRANE & CELL BIOLOGY 2000, vol. 13, no. 3, 2000, pages 379 - 387, XP009098978, ISSN: 1023-6597 * |
| ROGACHEVSKII I V ET AL: "Quantum-chemical study of the equilibrium geometry and electronic structure of certain [gamma]-pyrone derivatives", RUSSIAN JOURNAL OF GENERAL CHEMISTRY, NAUKA/INTERPERIODICA, MO, vol. 76, no. 11, 1 November 2006 (2006-11-01), pages 1820 - 1833, XP019468092, ISSN: 1608-3350 * |
| V. ROGACHEVSKY, V. B. PLAKHOVA, S. A. PODZOROVA: "METAL-BOUND FORMS OF 4H-PYRAN-4-ONE DERIVATIVES MODULATE NOCICEPTIVE RESPONSES OF SENSORY NEURONS", TECHNOLOGIES OF THE 21ST CENTURY-BOOK OF ABSTRACTS, 27 September 2005 (2005-09-27), pages 77 - 80, XP002477283, Retrieved from the Internet <URL:http://www.infran.ru/meetings/Abstracts-AvH.pdf> [retrieved on 20080418] * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008038160A2 (fr) | 2008-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6271240B1 (en) | Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals | |
| JP4898073B2 (ja) | 鼻内投与用フェンタニル組成物 | |
| CN101534809B (zh) | 取代的2-氨基1,2,3,4-四氢化萘在制备预防、减轻和/或治疗各类疼痛的药物中的用途 | |
| HK1139871A1 (en) | Improvements in and relating to medicinal compositions | |
| WO2003080022A3 (fr) | Analgesiques | |
| JP2006231070A5 (fr) | ||
| JP5306207B2 (ja) | 無針薬物送達デバイスにおけるオピオイド製剤の使用 | |
| WO2007098479A3 (fr) | Délivrance localisée d'insuline pour guérison osseuse | |
| WO2003079976A3 (fr) | Substance ayant une action sedative | |
| MX2009009132A (es) | Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona. | |
| JP5134973B2 (ja) | 医薬の組み合わせでの処置方法およびこれに適する医薬の組み合わせ | |
| US20150352040A1 (en) | Topical peripheral neuro-affective (tpna) therapy | |
| CA2570474A1 (fr) | Compositions comprenant du paracetamol et de l'ibuprofene | |
| JP4173538B2 (ja) | 痛みの管理及び解毒のためのケタミンの点鼻及び点眼投与 | |
| JP2016505050A5 (fr) | ||
| JP2003176227A (ja) | 製薬組成物、喫煙を控えている患者の喫煙禁断症状を軽減する方法及び患者の喫煙禁断症状を軽減するキット | |
| CN104758445A (zh) | 一种烟叶提取物及其在依赖治疗中的应用 | |
| Maseeh et al. | A review of smoking cessation interventions | |
| WO2008038160A3 (fr) | Substance à effet sédatif | |
| ES2274064T3 (es) | Combinacion de principios activos para la terapia medicamentosa de la dependencia a la nicotina. | |
| US20220175755A1 (en) | Methods of treating tobacco smoking addiction, and treating nicotine and tobacco smoking addiction | |
| US20160058752A1 (en) | Topical peripheral neuro-affective (tpna) therapy for neuropathic conditions | |
| Bentz | Clonidine is more effective than placebo for long-term smoking cessation but has side effects/COMMENTARY | |
| RU2008103666A (ru) | Способ лечения острой аллергии и устройство для доставки лекарственного средства | |
| Wilken et al. | Smoking cessation—part III: pharmacotherapy of smoking cessation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| NENP | Non-entry into the national phase |
Ref country code: RU |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07859265 Country of ref document: EP Kind code of ref document: A2 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07859265 Country of ref document: EP Kind code of ref document: A2 |